268 related articles for article (PubMed ID: 32327179)
1. Biomarkers for Immunotherapy.
Bustamante-Alvarez JG; Owen DH
Thorac Surg Clin; 2020 May; 30(2):207-214. PubMed ID: 32327179
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.
Yang J; Chen J; Wei J; Liu X; Cho WC
Expert Opin Biol Ther; 2016 Oct; 16(10):1209-23. PubMed ID: 27426430
[TBL] [Abstract][Full Text] [Related]
3. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
4. Principles of Immunotherapy in Non-Small Cell Lung Cancer.
Hsu ML; Naidoo J
Thorac Surg Clin; 2020 May; 30(2):187-198. PubMed ID: 32327177
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
Yoneda K; Imanishi N; Ichiki Y; Tanaka F
J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736
[TBL] [Abstract][Full Text] [Related]
6. Monitoring immunotherapy outcomes with circulating tumor DNA.
Goldberg SB; Patel AA
Immunotherapy; 2018 Sep; 10(12):1023-1025. PubMed ID: 30185140
[No Abstract] [Full Text] [Related]
7. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice.
Passiglia F; Commendatore O; Vitali M; Conca R
Future Oncol; 2018 Jun; 14(13s):41-60. PubMed ID: 29989452
[TBL] [Abstract][Full Text] [Related]
9. Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors?
Rassy E; Mezquita L; Remon J; Besse B
Immunotherapy; 2019 Sep; 11(13):1149-1160. PubMed ID: 31361172
[TBL] [Abstract][Full Text] [Related]
10. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.
Soo RA; Lim SM; Syn NL; Teng R; Soong R; Mok TSK; Cho BC
Lung Cancer; 2018 Jan; 115():12-20. PubMed ID: 29290252
[TBL] [Abstract][Full Text] [Related]
12. Emerging biomarkers for immune checkpoint inhibition in lung cancer.
Cyriac G; Gandhi L
Semin Cancer Biol; 2018 Oct; 52(Pt 2):269-277. PubMed ID: 29782924
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
Chae YK; Pan A; Davis AA; Raparia K; Mohindra NA; Matsangou M; Giles FJ
Clin Lung Cancer; 2016 Sep; 17(5):350-361. PubMed ID: 27137346
[TBL] [Abstract][Full Text] [Related]
14. The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer.
Santana-Davila R; Chow LQ
Future Oncol; 2018 Feb; 14(3):191-194. PubMed ID: 29334785
[No Abstract] [Full Text] [Related]
15. Immune checkpoint blockade and biomarkers of clinical response in non-small cell lung cancer.
Hallqvist A; Rohlin A; Raghavan S
Scand J Immunol; 2020 Dec; 92(6):e12980. PubMed ID: 33015859
[TBL] [Abstract][Full Text] [Related]
16. [Immunotherapy for lung cancer].
Ostoros G
Magy Onkol; 2017 Jun; 61(2):153-157. PubMed ID: 28585617
[TBL] [Abstract][Full Text] [Related]
17. Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer.
Anagnostou VK; Brahmer JR
Clin Cancer Res; 2015 Mar; 21(5):976-84. PubMed ID: 25733707
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant and Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer.
Broderick SR
Thorac Surg Clin; 2020 May; 30(2):215-220. PubMed ID: 32327180
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy in the treatment of non-small cell lung cancer.
Sundar R; Soong R; Cho BC; Brahmer JR; Soo RA
Lung Cancer; 2014 Aug; 85(2):101-9. PubMed ID: 24880938
[TBL] [Abstract][Full Text] [Related]
20. [Advances of the Correlation between Driver Gene Status and Immunotherapy
in Non-small Cell Lung Cancer].
Chen J; Jiang D; Huang F
Zhongguo Fei Ai Za Zhi; 2019 Apr; 22(4):233-238. PubMed ID: 31014442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
